| Identification | Back Directory | [Name]
DFMO | [CAS]
66640-93-5 | [Synonyms]
DFMO
L-DFMO
L-RMI71782
EFLORNITINE
L-Eflornithine
H-DL-(F2ME)ORN-OH
DIFLUOROMETHYLORNITHINE
L-α-difluoromethylornithine
H-ALPHA-DIFLUORO-ME-DL-ORN-OH
ALPHA-DIFLUORO-ME-DL-ORNITHINE
L-alpha-Difluoromethylornithine
DL-ALPHA-DIFLUOROMETHYLORNITHINE
L-Ornithine, 2-(difluoromethyl)-
ALPHA-DIFLUOROMETHYL-DL-ORNITHINE
H-DL-(ALPHA-DIFLUOROMETHYL)ORN-OH | [Molecular Formula]
C6H12F2N2O2 | [MDL Number]
MFCD00221766 | [MOL File]
66640-93-5.mol | [Molecular Weight]
182.17 |
| Chemical Properties | Back Directory | [Boiling point ]
347.0±42.0 °C(Predicted) | [density ]
1.293±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
1.22±0.44(Predicted) |
| Hazard Information | Back Directory | [Uses]
L-Eflornithine (L-DFMO) is an enantiomer of Eflornithine. L-Eflornithine is an irreversible ornithine decarboxylase (ODC) inhibitor with a KD of 1.3±0.3 μM, and a Kinact of 0.15±0.03 min-1[1]. | [Biological Activity]
L-Eflornithine (L-DFMO) is the enantiomer of Eflornithine. L-Eflornithine is an irreversible ornithine decarboxylase (ODC) inhibitor with KD of 1.3±0.3 μM and Kinact of 0.15±0.03 min-1. | [in vivo]
The more potent L-Eflornithine is present at much lower concentrations in both plasma and cerebrospinal fluid (CSF) than those of the D-Eflornithine. The plasma concentrations of L-Eflornithine are on average 52% of the D -enantiomer concentrations. The typical oral clearances of L-Eflornithine and D-eflornithine are 17.4 and 8.23 liters/h, respectively. | [target]
KD: 1.3±0.3 μM (Ornithine decarboxylase, ODC) | [storage]
Store at -20°C | [References]
[1] Qu N, et al. Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine. Biochem J. 2003 Oct 15;375(Pt 2):465-70. DOI:10.1042/BJ20030382
[2] Jansson-L?fmark R, et al. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness. Antimicrob Agents Chemother. 2015 Feb;59(2):1299-307. DOI:10.1128/AAC.04101-14 |
|
|